Journal: Health Science Reports

Article Title: CD40LG as a Biomarker in Rheumatoid Arthritis: Links to Bone Destruction and Interstitial Lung Disease ‐ A Bioinformatic Analysis With Clinical Validation

doi: 10.1002/hsr2.71318

Figure Lengend Snippet: Comparison of the expression of genes in RA and RA synovial tissues. (A) There was no difference in CXCL 8 gene expression between RA and OA patients ( p = 0.097). (B) The CD40LG gene expression was higher in RA patients than in OA patients ( p = 0.002). (C) The ITGAX gene expression was higher in RA patients than in OA patients( p = 0.025). (D) There was no difference in IL6 gene expression between RA and OA patients( p = 0.687). (E)The PTPRC gene expression was higher in RA patients than in OA patients( p = 0.003). * p < 0.05; ** p < 0.01.

Article Snippet: The recombinant CD40LG (Novoprotein), ITGAX (Proteintech), and PTPRC (Novoprotein) proteins (0.1 μg/mL) were used to coat 96‐well plates overnight at 4°C, followed by blocking 5% BSA at 37°C for 1 h. After washing three times with PBST, 100 μl of 1:100 dilution serum was added to each well and incubated plates at 37°C for 1 h. After another triple PBST rinse, peroxidase‐conjugated affinipure goat anti‐human IgG (1:10,000; Jackson ImmunoResearch) was added to the wells and incubated at 37°C for 1 h. After triple PBST washes, add the color development solution, once the color appears, immediately apply the stop solution to terminate the reaction.

Techniques: Comparison, Expressing, Gene Expression

Journal: Health Science Reports

Article Title: CD40LG as a Biomarker in Rheumatoid Arthritis: Links to Bone Destruction and Interstitial Lung Disease ‐ A Bioinformatic Analysis With Clinical Validation

doi: 10.1002/hsr2.71318

Figure Lengend Snippet: Receiver operating characteristic (ROC) curve of the 5 specifically expressed hub genes. (A) ROC curves for CXCL8. (B) ROC curves for CD40LG. (C) ROC curves for PTPRC. (D) ROC curves for IL6. (E) ROC curves for ITGAX. (F) 5 genes ROC summary.

Article Snippet: The recombinant CD40LG (Novoprotein), ITGAX (Proteintech), and PTPRC (Novoprotein) proteins (0.1 μg/mL) were used to coat 96‐well plates overnight at 4°C, followed by blocking 5% BSA at 37°C for 1 h. After washing three times with PBST, 100 μl of 1:100 dilution serum was added to each well and incubated plates at 37°C for 1 h. After another triple PBST rinse, peroxidase‐conjugated affinipure goat anti‐human IgG (1:10,000; Jackson ImmunoResearch) was added to the wells and incubated at 37°C for 1 h. After triple PBST washes, add the color development solution, once the color appears, immediately apply the stop solution to terminate the reaction.

Techniques:

Journal: Health Science Reports

Article Title: CD40LG as a Biomarker in Rheumatoid Arthritis: Links to Bone Destruction and Interstitial Lung Disease ‐ A Bioinformatic Analysis With Clinical Validation

doi: 10.1002/hsr2.71318

Figure Lengend Snippet: Comparison of the relevant antibody levels in the serum of different patients. (A) Comparison of OD values of serum CD40LG, ITGAX and PTPRC in RA, OA, and the HC group. (B) ROC curve of CD40LG in RA patients. (C) Higher serum CD40LG antibody levels in RA patients with combined bone destruction and ILD. ns: no significant difference. * p < 0.05; **** p < 0.0001. ROC, receiver operating characteristic.

Article Snippet: The recombinant CD40LG (Novoprotein), ITGAX (Proteintech), and PTPRC (Novoprotein) proteins (0.1 μg/mL) were used to coat 96‐well plates overnight at 4°C, followed by blocking 5% BSA at 37°C for 1 h. After washing three times with PBST, 100 μl of 1:100 dilution serum was added to each well and incubated plates at 37°C for 1 h. After another triple PBST rinse, peroxidase‐conjugated affinipure goat anti‐human IgG (1:10,000; Jackson ImmunoResearch) was added to the wells and incubated at 37°C for 1 h. After triple PBST washes, add the color development solution, once the color appears, immediately apply the stop solution to terminate the reaction.

Techniques: Comparison

Journal: Health Science Reports

Article Title: CD40LG as a Biomarker in Rheumatoid Arthritis: Links to Bone Destruction and Interstitial Lung Disease ‐ A Bioinformatic Analysis With Clinical Validation

doi: 10.1002/hsr2.71318

Figure Lengend Snippet: Molecular docking 3D diagram of key targets and small molecule drugs. (A) CD40LG‐emetine complex, with binding energy of −7.1 kcal/mol. (B) CD40LG‐oligomycin complex, with binding energy of −7.2 kcal/mol. (C) CD40LG‐cromoglicic acid complex, with binding energy of −7.9 kcal/mol. (D) ITGAX‐sulfinpyrazone complex, with binding energy of −7.2 kcal/mol. (E) PTPRC‐oligomycin complex, with binding energy of −8.5 kcal/mol. (F) PTPRC‐buspirone complex, with binding energy of −7.0 kcal/mol. (G) PTPRC‐chlorogenic acid complex, with binding energy of −7.2 kcal/mol.

Article Snippet: The recombinant CD40LG (Novoprotein), ITGAX (Proteintech), and PTPRC (Novoprotein) proteins (0.1 μg/mL) were used to coat 96‐well plates overnight at 4°C, followed by blocking 5% BSA at 37°C for 1 h. After washing three times with PBST, 100 μl of 1:100 dilution serum was added to each well and incubated plates at 37°C for 1 h. After another triple PBST rinse, peroxidase‐conjugated affinipure goat anti‐human IgG (1:10,000; Jackson ImmunoResearch) was added to the wells and incubated at 37°C for 1 h. After triple PBST washes, add the color development solution, once the color appears, immediately apply the stop solution to terminate the reaction.

Techniques: Binding Assay